The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Open accessAbstract
BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This ADNI clinical characterization paper reports baseline and 12-month clinical, cognitive, and CSF biomarker data for 819 participants: 229 cognitively normal, 398 with MCI, and 192 with mild AD. It shows expected group differences at baseline, a 16.5% 12-month MCI-to-AD progression rate, and baseline CSF Aβ-42 predicting 12-month cognitive change in normal and MCI groups.
Key findings
- At baseline, ADAS-Cog total scores were 6.2 ± 2.9 in controls, 11.5 ± 4.4 in MCI, and 18.6 ± 6.3 in AD (p < 0.001); MCI subjects were most impaired on memory items and only mildly impaired in nonmemory domains.
- Over 12 months, 64 of 398 MCI subjects progressed to AD, a rate of 16.5% (95% CI 11.9%–20.5%); normal controls progressed to MCI at an estimated 1.4% (95% CI 0%–3.2%).
- ADAS-Cog 12-month change was −0.5 ± 3.0 in controls, 1.1 ± 4.4 in MCI, and 4.3 ± 6.6 in AD (p < 0.001).
- Baseline CSF Aβ-42 decreased across groups (controls 206 ± 5, MCI 164 ± 4, AD 143 ± 4 pg/mL; p < 0.001), and higher baseline Aβ-42 was associated with better ADAS-Cog performance and smaller 12-month change in normal subjects and MCI.
Methods
- Multicenter ADNI cohort of 819 subjects aged 55–90 enrolled at baseline and classified as cognitively normal, MCI, or mild AD using standard clinical, cognitive, and functional criteria; subjects were followed for 12 months with cognitive and functional measures, MRI/PET in subsets, and lumbar puncture in a minimum of 20% per site.
- Baseline group comparisons used nonparametric tests (Kruskal-Wallis) with Hochberg multiple comparisons and exact tests for proportions; 12-month change was summarized as conversion proportion, baseline-to-12-month mean or percent difference, and rate per year from mixed-effects regression models.
- Annual conversion rates were estimated using a hybrid interval-censored method; CSF Aβ-42 was related to diagnosis, ADAS-Cog performance, and 12-month ADAS-Cog change.
Limitations
- The paper states that a 12-month change period is not sufficient to draw conclusions about the likelihood of clinical change, and that the ADNI cohort likely does not represent “typical” community subjects because participants were more highly educated, mostly white, and had a high proportion of APOE4 carriers in the MCI and AD groups.
- The paper also states that the MCI criteria required a stringent degree of memory impairment, so these subjects were likely further along the clinical spectrum and more likely to progress than less-impaired MCI subjects.
- Evident from the text: CSF analyses were limited to subsets (baseline n = 114 controls, 199 MCI, 102 AD), and some subjects lacked 12-month follow-up diagnoses (17 controls and 41 MCI subjects), which limits interpretation of conversion and biomarker results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 8 Sources not found · 8 Own interpretation · 5 No basis given · 3 Not checked yet · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“successfully predicted the 12-month change in cognitive measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but they looked more like the AD group for change in digit span, category fluency, and trail making”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonmemory cognitive measures were only minimally impaired in the subjects with MCI.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“The neuropsychological battery indicated that, in general, subjects with MCI were more impaired than controls on the memory items and were only mildly impaired in nonmemory domains (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sub-jects with AD were impaired in virtually all of the cognitive areas tested.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline CSF measures of A-42 separated the 3 groups as expected”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The next greatest area of impairment for the subjects with MCI resulted from the executive function domain.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI also remained relatively stable as a group, and the subjects with mild AD showed a decline on most of these measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interaction of A-42 and time also had a significant effect on ADAS-Cog scores in subjects with MCI ( p ϭ 0.00), but not in normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CDR sum of the boxes essentially did not change in the normal control group (0.1) and increased by approximately 0.7 points in the subjects with MCI and 1.5 points in the subjects with AD ( p Ͻ 0.001).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the normal group stayed nearly the same, and the AD group worsened significantly compared to the normal controls.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and more like the normal controls for the clock test and global CDR.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, subjects with MCI had a mean total Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score of 11.5, while the normal control subjects had a score of 6.2 and the subjects with mild AD had a score of 18.7 ( p Ͻ 0.001, table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cholinesterase inhibitors-normal controls 0%, subjects with MCI 43.7%, subjects with AD 84.9%”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 819 subjects were recruited and received a baseline evaluation as part of the ADNI study.”
- Also stated in: § RESULTS Baseline characteristics. · plain
“There were 229 normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD enrolled.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated premorbid verbal IQ of these subjects was quite high, at almost 120 for the normal control subjects, 116 for the subjects with MCI, and 114 for the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedgedn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001, with normal controls performing best, subjects with AD worst, and subjects with MCI in the middle.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MCI group was more variable; in most cases they worsened more than the normal group but not as much as the AD group”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 50% of the subjects with MCI were on antidementia therapies.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the subjects in the study were white, and this was approximately equivalent across the groups.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in table 2, the mean age of the 3 groups was equivalent at approximately 75 years.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there were more men than women in the MCI group (64.6% men vs 35.4% women).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was somewhat less variability on the global measures, while some of the individual neuropsychological tests such as the AVLT showed considerable variability among the subjects despite relatively modest mean group changes.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CSF A-42 levels were assessed at baseline and were correlated with clinical diagnoses, performance on the ADAS-Cog, and changes in performance on the ADAS-Cog over 1 year (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Delayed recall improved by 5.3% in the normal control group and declined by 4.8% in the subjects with MCI and 7.2% in the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As such, the baseline characteristics of the subjects indicated that the 3 groups were generally well educated, intelligent, and mostly white, and perform in a fashion similar to subjects recruited for typical clinical trials.[25][26][27][28]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim have been checked yet.
In the paper
“They tend to be more highly educated and the proportion of APOE4 carriers was quite high in the MCI and AD groups but is consistent with subjects recruited for clinical trials.25”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the memory measures such as the AVLT, there was virtually no change across 12 months in learning in the normal control group with a decreased learning of 1.3 items in the subjects with MCI and 3.7 fewer items learned in the AD group.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional 8 subjects with MCI reverted to a normal classification over that interval, and 41 did not have a follow-up diagnosis.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“may allow detection of the neurodegenerative process at an earlier point in the spectrum”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All hypothesis tests were 2-sided at level 0.05, and models were validated both graphically and analytically.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Data analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Most investigators believe that Alzheimer disease (AD) is a slowly evolving process that likely begins years to decades before the clinical symptoms are manifest.1”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 12month change period is not a sufficient amount of time to draw conclusions regarding the likelihood of clinical change.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“has been a target for clinical trials.[2][3][4][5]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The diagnostic conversions over the 12-month period must be viewed with some caution.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This might be a useful technique to reduce the numbers of subjects used in clinical trials to detect a clinical effect of therapeutic interventions.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Mild cognitive impairment (MCI) represents an attempt to characterize subjects at an early clinical phase”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
The paper relies on this without support.
The expected 12-month progression rate for MCI was approximately 16.5% per year.
“The 12-month progression rate of MCI was as predicted”
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
The paper relies on this without support.
The baseline characteristics observed in the recruited cohorts matched the characteristics anticipated for normal, MCI, and AD cohorts.
“The Alzheimer's DiseaseNeuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics.”
The paper relies on this without support.
The MCI subjects have an underlying Alzheimer's disease process that drives clinical progression.
“As such, these subjects were likely further down the clinical spectrum with respect to the underlying AD process such that they would be more likely to progress than subjects with less impairment in the MCI spectrum.”
The paper relies on this without support.
CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Among the 398 subjects with MCI at baseline, 64 progressed to AD at 12 months”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Table 5 Baseline measures on subjects according to progression status at 1 year Assortment variable Nonprogressors, mean ؎ SD (n ؍ 329) Progressors, mean ؎ SD (n ؍ 69)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“the subjects with mild AD had a score of 18.7”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“ADAS-Cog total 6.2 Ϯ 2.9 11.5 Ϯ 4.4 18.1 18.6 Ϯ 6.3 14.0 Ͻ0.001 a, b, c”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“subjects with MCI (r ϭ Ϫ0.22; 95% CI Ϫ0.035 to Ϫ0.08)”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“95% CI Ϫ0.035 to Ϫ0.08”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“GDS Score 0.8 Ϯ 1.1 1.6 Ϯ 1.4 7.3 1.7 Ϯ 1.4 0.6 Ͻ0.001 a, b”
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Self-citationL’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,299
Cited by
Sorted by citations
Items 1,101–1,200 of 2,570
Fair Machine Learning in Healthcare: A Survey
Feng, Q., Du, M., Zou, N., & Hu, X. (2025) · IEEE Transactions on Artificial Intelligence · doi:10.1109/tai.2024.3361836 · Cited by 12
Learning neuroimaging models from health system-scale data
Lyu, Y., Harake, E. S., Chowdury, A., Banerjee, S., Gologorsky, R., Liu, S., Meißner, A.-K., Rao, A., Zhao, C., Kondepudi, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01608-0 · Cited by 16
Oh, S. L., Zhou, M., Chin, E. W. M., Amarnath, G., Cheah, C. H., Ng, K. P., Kandiah, N., Goh, E. L. K., & Chiam, K. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.875895 · Cited by 12
Association of the top 20 Alzheimer's disease risk genes with [18F]flortaucipir PET
Stage, E., Risacher, S. L., Lane, K. A., Gao, S., Nho, K. T., Saykin, A. J., Apostolova, L. G., & Initiative, A. D. N. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12308 · Cited by 11
Lu, Y., & Initiative, A. D. N. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02202-z · Cited by 12
Xu, X., Wang, H., Bennett, D. A. A., Zhang, Q., Meng, X., & Zhang, H. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.03.002 · Cited by 11
“ADNI is a longitudinal multicenter study to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and follow-up of AD [17].”
BackgroundDing, J., Shen, C., Wang, Z., Yang, Y., Fakhri, G. E., Lu, J., Liang, D., Zheng, H., Zhou, Y., Sun, T., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad312 · Cited by 13
“The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Petersen et al. 2010) provided the data in this study.”
Image processing: an early detection tool for Alzheimer’s disease
Ballav, S., Biswas, B., Dey, S., Sahu, V. K., & Basu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00001-6 · Cited by 13
Liu, S., Zheng, Y., Li, H., Pan, M., Fang, Z., Liu, M., Qiao, Y., Pan, N., Jia, W., & Ge, X. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.09.003 · Cited by 13
NeuropsychBrainAge: A biomarker for conversion from mild cognitive impairment to Alzheimer's disease
Condado, J. G., Cortés, J. M., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12493 · Cited by 12
Li, Q., Su, S., Feng, Y., Jia, M., Zhan, J., Liao, Z., Li, J., Li, X., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14056 · Cited by 13
The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative
Wang, Y. T., Ye, M., Ji, Q., Liu, Q., Xu, X., & Zhan, Y. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01506-8 · Cited by 13
A whole‐brain functional connectivity model of Alzheimer's disease pathology
Prakash, R. S., McKenna, M. R., Gbadeyan, O., Shankar, A., Pugh, E., Teng, J., Andridge, R., Berry, A. S., & Scharre, D. W. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14349 · Cited by 12
Simulations of Common Unsupervised Domain Adaptation Algorithms for Image Classification
Chaddad, A., Wu, Y., Jiang, Y., Bouridane, A., & Desrosiers, C. (2025) · IEEE Transactions on Instrumentation and Measurement · doi:10.1109/tim.2025.3527531 · Cited by 12
Alifuse: Aligning and Fusing Multimodal Medical Data for Computer-Aided Diagnosis
Chen, Q., & Yi, H. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10821851 · Cited by 15
Jumaili, M. L. F., & Sonuç, E. (2025) · Computers, materials & continua/Computers, materials & continua (Print) · doi:10.32604/cmc.2025.062719 · Cited by 13
Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges
Bellio, M., Oxtoby, N. P., Walker, Z., Henley, S. M. D., Ribbens, A., BLANDFORD, A. E., Alexander, D. C., & Yong, K. X. X. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12135 · Cited by 12
Adversarial counterfactual augmentation: application in Alzheimer’s disease classification
Xia, T., Sanchez, P. L., Qin, C., & Tsaftaris, S. A. (2022) · Frontiers in Radiology · doi:10.3389/fradi.2022.1039160 · Cited by 12
“We use the ADNI dataset [21] for experiments.”
LESA: Longitudinal Elastic Shape Analysis of Brain Subcortical Structures
Zhang, Z., Wu, Y., Xiong, D., et al. (2022) · Journal of the American Statistical Association · doi:10.1080/01621459.2022.2102984 · Cited by 12
Automated Analysis of Drawing Process for Detecting Prodromal and Clinical Dementia
Yamada, Y., Kobayashi, M., Shinkawa, K., Nemoto, M., Ota, M., Nemoto, K., & Arai, T. (2022) · IEEE International Conference on Digital Health (ICDH) · doi:10.1109/icdh55609.2022.00008 · Cited by 12
Multiparametric Quantitative Imaging Biomarker as a Multivariate Descriptor of Health: A Roadmap
Raunig, D. L., Pennello, G. A., Delfino, J. G., Buckler, A. J., Hall, T. J., Guimarães, A. R., Wang, X., Huang, E. P., Barnhart, H. X., deSouza, N. M., et al. (2022) · Academic Radiology · doi:10.1016/j.acra.2022.10.026 · Cited by 12
Weight Loss and Alzheimer’s Disease in Down Syndrome
Fleming, V., Helsel, B. C., Ptomey, L. T., Rosas, H. D., Handen, B. L., Laymon, C. M., Christian, B. T., Head, E., Mapstone, M. E., Lai, F., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220865 · Cited by 12
Protein-Balanced Dietary Habits Benefit Cognitive Function in Japanese Older Adults
Sakurai, K., Okada, E., Anzai, S., Tamura, R., Shiraishi, I., Inamura, N., Kobayashi, S., Sato, M., Matsumoto, T., Kudo, K., et al. (2023) · Nutrients · doi:10.3390/nu15030770 · Cited by 14
Jann, K., Boudreau, J., Albrecht, D., Cen, S., Cabeen, R. P., Ringman, J. M., Wang, D. J., & Initiative, T. A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220851 · Cited by 13
The role of human cognitive neuroscience in drug discovery for the dementias
Wesnes, K. A., & Edgar, C. J. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.12.001 · Cited by 12
Pérez-González, J., Yáñez-Suárez, Ó., Bribiesca, E., et al. (2014) · Journal of medical imaging · doi:10.1117/1.jmi.1.3.034002 · Cited by 12
The Clinical Value of Large Neuroimaging Data Sets in Alzheimer's Disease
Toga, A. W. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.008 · Cited by 12
Self-citationAnomaly detection for the individual analysis of brain PET images
Burgos, N., Cardoso, M. J., Samper‐Gonzàlez, J., Habert, M., Durrleman, S., Sebastien Ourselin, A., & Colliot, O. (2021) · Journal of medical imaging · doi:10.1117/1.jmi.8.2.024003 · Cited by 12
Venkatraghavan, V., Vinke, E. J., Bron, E. E., Niessen, W. J., Ikram, M. A., Klein, S., & Vernooij, M. W. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118233 · Cited by 12
Zamani, J., Sadr, A., & Javadi, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-04943-3 · Cited by 13
A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
Brum, W. S., Bastiani, M. A. D., Bieger, A., Therriault, J., Ferrari‐Souza, J. P., Benedet, A. L., Saha‐Chaudhuri, P., Souza, D. O., Ashton, N. J., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12270 · Cited by 12
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12
Italian, European, and international neuroinformatics efforts: An overview
Redolfi, A., Archetti, D., Francesco, S. D., Crema, C., Tagliavini, F., Lodi, R., Ghidoni, R., Wheeler‐Kingshott, C. A. M. G., Alexander, D. C., & D'Angelo, E. U. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15854 · Cited by 12
“…through several phases: ADNI-1 (2004 – 2009) collected demographic, clinical, biological and cognitive data from 800 subjects across the AD spectrum (Petersen et al., 2010), followed by ADNI-GO (2009 – 2011, 200 subjects) (Jack et al., 2010), ADNI-2 (2011 – 2016, 700 subjects) (Aisen et al.,…”
MethodDynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
Tang, L., Wang, Z., Ma, L., Cao, X., Tan, L., & Tan, M. (2022) · BMC Neurology · doi:10.1186/s12883-022-03038-w · Cited by 13
Initiative, A. D. N., Seo, E. H., & Choo, I. H. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3261-9 · Cited by 12
“Detailed eligibility criteria for aMCI are described elsewhere [16].”
BackgroundMatsumoto, L., Suzuki, K., Mizuno, Y., Ohike, Y., Ozeki, A. N., Ono, S., Takanashi, M., Sawaki, D., Suzuki, T., Yamazaki, T., et al. (2017) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13142 · Cited by 12
Neuromorphologicaly-preserving Volumetric data encoding using VQ-VAEPreprint
Tudosiu, P.-D., Varsavsky, T., Shaw, R., Graham, M. S., Nachev, P., Sebastien Ourselin, A., Sudre, C. H., & Cardoso, M. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2002.05692 · Cited by 12
The Ontario Neurodegenerative Disease Research InitiativePreprint
Sunderland, K. M., Beaton, D., Arnott, S. R., Kleinstiver, P. W., Kwan, D. T., Lawrence‐Dewar, J. M., Ramirez, J., Tan, B., Bartha, R., Black, S. E., et al. (2020) · medRxiv · doi:10.1101/2020.07.30.20165456 · Cited by 15
“S-UPDRS: Part 3g (/132) median (range) [missing] 4 (0-15) [4] 2 (0-21) [13] 12 (0-64) [14] 4 (0-26) [2] 3.”
GastroHUN an Endoscopy Dataset of Complete Systematic Screening Protocol for the Stomach
Bravo, D., Ordoñez, J. S. F., Vera, F., Trejos, J. S. E., Martı́nez, C. P., Gómez, M., Gonzalez, F. A., & Romero, E. (2025) · Scientific Data · doi:10.1038/s41597-025-04401-5 · Cited by 13
MCI Criteria in ADNI: Meeting Biological Expectations.
Petersen, R. C. (2021) · PubMed Central · doi:10.1212/wnl.0000000000012588 · Cited by 11
Self-citationHeston, M. B., Teague, J. P., Cody, K. A., Deming, Y. K., Chavez, E. R. D., Morse, J., Chin, N. A., Engelman, C. D., Chappell, R. J., Langhough, R. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70551 · Cited by 11
Trends and applications of variational autoencoders in medical imaging analysis
Yeoh, P. S. Q., Hasikin, K. B., Wu, X., Goh, S. L., & Lai, K. W. (2025) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2025.102647 · Cited by 12
Alhasan, M. S., Alhasan, A. S., Milburn, J. M., Khalil, M., Almaghraby, A., Alharthi, O. A., Hamoud, S., Essibayi, M. A., Elhassan, Y. H., Feltrin, F. S., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100400 · Cited by 12
Afifi, I., Elgendy, M. A., Abdelfatah, M., & El–Sappagh, S. (2025) · Brain Informatics · doi:10.1186/s40708-025-00286-7 · Cited by 17
Teng, E., Manser, P. T., Shah, M. V., Pickthorn, K., Hu, N., Djakovic, S., Swendsen, H., Blendstrup, M., Faccin, G., Ostrowitzki, S., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.101 · Cited by 11
Masuda, H., Mori, M., Hirano, S., Uzawa, A., Uchida, T., Muto, M., Ohtani, R., Aoki, R., Hirano, Y., (J-ADNI), J. A. D. N. I., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38893-1 · Cited by 11
Pearson, M. J., Wagstaff, R. A., Williams, R. J., & Initiative, A. D. N. (2024) · Brain and Behavior · doi:10.1002/brb3.3611 · Cited by 11
Zhang, Z., Sheng, Z.-H., Liu, J. Y., Zhang, D., Wang, H., Wang, L., Zhu, Y., Ma, L., & Tan, L. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241284216 · Cited by 11
Vito, A. N. D., Kunicki, Z. J., Joyce, H. E., Huey, E. D., Jones, R. N., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14568 · Cited by 12
Guo, Y., Liu, T., Chen, H., Zhou, L., Huang, W., Zhang, K., Wang, X., wang, Y., Zhou, J. H., & Chen, F. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111295 · Cited by 13
Shadyab, A. H., Aslanyan, V., Jacobs, D. M., Salmon, D. P., Morrison, R. H., Katula, J. A., Jin, S., Thomas, R. G., LaCroix, A. Z., Pa, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70118 · Cited by 12
Artificial intelligence in drug development for delirium and Alzheimer’s disease
Ai, R., Xiao, X., Deng, S., Yang, N., Xing, X., Watne, L. O., Selbæk, G., Wedatilake, Y., Xie, C., Rubinsztein, D. C., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.026 · Cited by 11
Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease
Nakashima, S., Sato, K., Niimi, Y., Ihara, R., Suzuki, K., Iwata, A., Toda, T., Iwatsubo, T., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70102 · Cited by 11
Explainable Diagnosis of Alzheimer’s Disease Using Graph Kolmogorov-Arnold Networks
Ding, T. K., Xiang, D., Schubert, K. E., & Dong, L. F. (2025) · Communications in computer and information science · doi:10.1007/978-3-031-99879-9_1 · Cited by 11
Zhang, B., Zhang, J., Zhao, H., Zhang, X., Li, M., Qian, L., Wang, K., Tian, C., Guo, W., Cao, Q., et al. (2011) · Acta Radiologica · doi:10.1258/ar.2011.100430 · Cited by 11
Effect of Feru‐guard 100M on amyloid‐beta deposition in individuals with mild cognitive impairment
Matsuyama, K., Yamamoto, Y., & Sora, I. (2020) · Psychogeriatrics · doi:10.1111/psyg.12581 · Cited by 11
Apolipoprotein E ɛ4–related effects on cognition are limited to the Alzheimer’s disease spectrum
Fernández, A., Vaquero, L., Bajo, R., Zuluaga, P., Initiative, A. D. N., Weiner, M. W., Saykin, A. J., Trojanowski, J. Q., Shaw, L. M. J., Toga, A. W., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00450-x · Cited by 10
Self-citationSanderson‐Cimino, M. E., Elman, J. A., Tu, X. M., Gross, A. L., Panizzon, M. S., Gustavson, D. E., Bondi, M. W., Edmonds, E. C., Eppig, J. S., Franz, C. E., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.847315 · Cited by 13
Kim, H., Initiative, O. B. O. T. A. D. N., Levine, A., Cohen, D., Gehrman, P., Zhu, X., Devanand, D. P., Lee, S., & Goldberg, T. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215417 · Cited by 14
“Adetaileddescription of the ADNI cohort has been previously published [28].”
Picture‐naming test for a linguistically diverse population with cognitive impairment and dementia
Paplikar, A., Varghese, F. A., Alladi, S., et al. (2022) · International Journal of Language & Communication Disorders · doi:10.1111/1460-6984.12728 · Cited by 11
Xu, X., Wang, H., Bennett, D. A., Zhang, Q., Wang, G., & Zhang, H. (2022) · Biomedicines · doi:10.3390/biomedicines10081782 · Cited by 11
Li, M., Jiang, Y., Li, X., Yin, S., & Luo, H. (2022) · Medical Physics · doi:10.1002/mp.15985 · Cited by 11
Gao, L., Hu, Z., Li, R., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12101348 · Cited by 11
Al‐Yawer, F., Pichora-Fuller, M. K., Wittich, W., Mick, P. T., Giroud, N., Rehan, S., & Phillips, N. A. (2022) · Ear and Hearing · doi:10.1097/aud.0000000000001322 · Cited by 15
“It was previously believed that MCI is more prevalent in males (Petersen et al. 2010); however, a recent meta-analysis (Au et al.”
BackgroundResultLuo, T., Tu, Y., Huang, S., Ma, Y., Wang, Q., Wang, Y., Wang, J., & Initiative, A. D. N. (2023) · European Journal of Neurology · doi:10.1111/ene.15868 · Cited by 13
Global biomarker trends in Alzheimer’s research: A bibliometric analysis
Noda, K., Lim, Y., Sengoku, S., & Kodama, K. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103677 · Cited by 11
Trends in Brain Research: A Bibliometric Analysis
Simard, M., Kozlowski, D., Segal, J., Messer, M., Ocay, D. D., Saari, T., Ferland, C. E., & Larivière, V. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.314 · Cited by 12
Membreno, R., Thomas, K. R., Calcetas, A. T., Edwards, L., Bordyug, M., Showell, M., Stanfill, M., Brenner, E. K., Walker, K. S., Rotblatt, L. J., et al. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000585 · Cited by 11
Random Forest and Gene Networks for Association of SNPs to Alzheimer’s Disease
de Araújo, G. S., Souza, M. R. B., de Oliveira, J. R. M., & Costa, I. G. (2013) · Lecture notes in computer science · doi:10.1007/978-3-319-02624-4_10 · Cited by 12
A Spatial Registration Toolbox for Structural MR Imaging of the Aging Brain
Initiative, A. D. N., Ganzetti, M., Liu, Q., et al. (2018) · Neuroinformatics · doi:10.1007/s12021-018-9355-3 · Cited by 11
“For detailed information regarding acquisition parameters at each different site, please refer to (Petersen et al. 2010; Weiner et al. 2012).”
BackgroundA Time-Sensitive Hybrid Learning Model for Patient Subgrouping
Zhang, Y., Zhou, H., Li, J., Sun, W., & Chen, Y. (2018) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn.2018.8488991 · Cited by 11
Ineichen, B. V., Sati, P., Granberg, T., Absinta, M., Lee, N. J., Lefeuvre, J., & Reich, D. S. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102371 · Cited by 11
“A growing number of large cooperatives, including the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Human Connectome Project (HPC) (Petersen et al., 2010; Van Essen et al., 2013) aim to standardize reporting on neuroimaging in humans.”
BackgroundRoss, D. E., Seabaugh, J. D., Seabaugh, J. M., Barcelona, J., Seabaugh, D., Wright, K., Norwind, L., King, Z., Graham, T. J., Baker, J. R., et al. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.715807 · Cited by 11
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
Schneider, L. S. S. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.002 · Cited by 11
Michaud, T. L., Initiative, A. D. N., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150066 · Cited by 10
“The study (ADNI 1) enrolled 192 patients with mild AD, 398 with MCI, and 229 with no cognitive impairment [29].”
Noa, J. A. S., Rodríguez, J. J. L., Pérez, S. S., & Romero, J. S. (1999) · PubMed · Cited by 11
Russo, M. J., Cohen, G., Chrem, P., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s107051 · Cited by 11
Bouallègue, F. B., Vauchot, F., Mariano-Goulart, D., & Payoux, P. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9833-0 · Cited by 12
Bundle-specific fornix reconstruction for dual-tracer PET-tractometryPreprint
Rheault, F., Roy, M., Cunnane, S. C., & Descoteaux, M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/423459 · Cited by 11
“However, existing databases, such as Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Petersen et al., 2010), often use classical diffusion MRI (dMRI) acquisitions tailored for diffusion tensor imaging (DTI) processing (Sudlow et al., 2015; Marek et al., 2011).”
MethodWen, J., Yang, Z., Nasrallah, I. M., Cui, Y., Erus, G., Srinivasan, D., Abdulkadir, A., Mamourian, E., Skampardoni, I., Hwang, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.16.508329 · Cited by 12
Self-citationEvaluation of Image‐Level Harmonization Methods for Multi‐Center MR Neuroimaging
Ho, B., Kim, D., Kumar, A., Weiss, S. E., Vossler, H. A., Mormino, E. C., Zaharchuk, G., & Initiative, T. F. L. D. N. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70221 · Cited by 10
Pérez‐Millan, A., Contador, J., Tudela, R., Niñerola‐Baizán, A., Setoaín, X., Lladó, A., Sánchez‐Valle, R., & Sala‐Llonch, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-18129-4 · Cited by 10
Nuvoli, S. M. F., Bianconi, F., Rondini, M., Lazzarato, A., Marongiu, A., Fravolini, M. L., Cascianelli, S., Amici, S., Filippi, L., Spanu, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102425 · Cited by 10
Balajoo, S. M., Eickhoff, S. B., Masouleh, S. K., Plachti, A., Waite, L. K., Saberi, A., Bahri, M. A., Bastin, C., Salmon, É., Hoffstaedter, F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13056 · Cited by 11
Sanderson‐Cimino, M. E., Chen, R., Tu, X. M., Elman, J. A., Jak, A. J., & Kremen, W. S. (2023) · Neuropsychology · doi:10.1037/neu0000903 · Cited by 10
Heterogeneity of Alzheimer’s disease identified by neuropsychological test profiling
Nguyen, T. T. T., Lee, H., Huang, L., Hu, C., Yeh, C.-Y., Yang, W. V., & Lin, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292527 · Cited by 13
“…Memory" item, which only required participants to recall three words and five objects, compared to the more exhaustive Rey Auditory Verbal Learning Test and Logical Memory test used in the multisite ADNI study, which assess the ability to recall 15 words and a short story, respectively [44–46].”
Generalizable Links Between Borderline Personality Traits and Functional Connectivity
Shafiei, G., Keller, A. S., Bertolero, M. A., Shanmugan, S., Bassett, D. S., Chen, A. A., Covitz, S. C., Houghton, A., Luo, A. C., Mehta, K. P., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.02.1016 · Cited by 13
“…datasets in healthy populations and clinical cohorts [e.g., ADNI (Alzheimer ’ s Disease Neuroimaging Initiative) for Alzheimer ’ s disease (42), PPMI (Parkinson Progression Marker Initiative) for Parkinson ’ s disease (43), and the ENIGMA (Enhancing Neuro Imaging Genetics through Meta…”
BackgroundHarrison, T. M., Chadwick, T. A., Pezzoli, S., Lee, J., Landau, S. M., Jagust, W. J., & Initiative, A. D. N. (2024) · Annals of Neurology · doi:10.1002/ana.26964 · Cited by 10
Self-citationPrevalence of neurocognitive disorders 5 years after elective orthopaedic surgery
Atkins, K. J., SILBERT, B. S., Scott, D. A. H., & Evered, L. A. (2024) · Anaesthesia · doi:10.1111/anae.16365 · Cited by 10
Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 10
Liu, T., Wang, M., Zhang, J., Ye, C., Funahashi, S., Liu, J., Wang, L., Yan, T., & Initiative, T. A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14227 · Cited by 10
Anatomical foundation models for brain MRIs
Barbano, C. A., Brunello, M., Dufumier, B., & Grangetto, M. (2025) · Pattern Recognition Letters · doi:10.1016/j.patrec.2025.11.028 · Cited by 22
“The experimental data is gathered from different publicly available datasets, and we target 5 different neurological conditions: healthy samples (OpenBHB [13]), Alzheimer’s Disease (ADNI [23] and OASIS-3 [20]), schizophrenia (SchizConnect [30]) and Autism Spectrum Disorder (ABIDE I [9]).”
Progression of hippocampal subfield atrophy and asymmetry in Alzheimer's disease
Xu, J., Tan, S., Wen, J., Zhang, M., Initiative, A. D. N., & Xu, X. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16543 · Cited by 10
Yu, S., Wu, J., Shao, Y., Qiu, D., Qin, Z. S., & Initiative, T. A. D. N. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012527 · Cited by 12
“To demonstrate its utility, we performed a large classification-based GWAS on brain MR images using publicly available datasets from the ADNI study [22] including 1,009 individuals.”
Quispialaya, K. M., Therriault, J., Aliaga, A., Tissot, C., Servaes, S., Rahmouni, N., Karikari, T. K., Benedet, A. L., Ashton, N. J., Macedo, A. C., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16255 · Cited by 12
Huszár, Z., Solomon, A., Engh, M. A., Koszovácz, V., Terebessy, T., Molnár, Z., Hegyi, P., Horvath, A. A., Mangialasche, F., Kivipelto, M., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01602-9 · Cited by 12
Escarcega, R. D., J., V. K. M., Kyriakopoulos, V. E., Ortiz, G. J., Gusdon, A. M., Fan, H., Peesh, P., Conesa, M. P. B., Colpo, G. D., Ahnstedt, H. W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106747 · Cited by 11
“The conversion rate from MCI to dementia in 12 months is 5 – 39 % (Petersen et al., 2010; Thaipisuttikul et al., 2022; Bruscoli and Love-stone, 2004; Mitchell and Shiri-Feshki, 2009; Roberts et al., 2014; Han et al., 2012; Tokuchi et al., 2014; Pandya et al., 2016).”
Henríquez, P. A., & Araya, N. (2024) · PeerJ Computer Science · doi:10.7717/peerj-cs.2590 · Cited by 12
Shvetcov, A., Thomson, S., Cho, A., Wilkins, H., Reed, J. H., Swerdlow, R. H., Brown, D. A., Initiative, T. A. D. N., & Finney, C. A. (2024) · Aging Cell · doi:10.1111/acel.14439 · Cited by 11
Metadata
- Authors
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2010-01-19
- Volume
- 74
- Issue
- 3
- Pages
- 201-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2809036
- OpenAlex
- W2122328291
- Cited by
- 2,572
- References
- 27
- Citations by year
- 2026: 312 · 2025: 391 · 2024: 327 · 2023: 254 · 2022: 233 · 2021: 209 · 2020: 182 · 2019: 121 · 2018: 85 · 2017: 67 · 2016: 71 · 2015: 66 · 2014: 45 · 2013: 63 · 2012: 59
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (AG024904)
- National Institutes of Health (5r01ag027984-03, 5r01ag030048-05, n01mh22005-16-0-1, 5r01dk075128-05, 5u01ag006786-38, 5r01mh083552-05, 5r01ca104573-05, 5p30ag010124-30, 5p01ag009215-20, 5r01ag011378-25, 5p41rr023953-04, 5u01ag024904-10, 5u01ag029213-05, 5r01ag016381-08, 5r01eb006266-04, 5r01ag010897-27, AG024904, 5p01ag019724-23, 5p30ca093373-23, 5p50ag016574-20)
- National Institute on Aging (AG027984, U01-AG-024904, R01AG11378, P30AG010129, U19 AG010483, U01‐AG10483, R01-AG030048, P50‐AG16574, P01 & AG019724, U01AG06786, P50-AG23501, RC1AG035427, AG 010483, R01AG031224, AG031224, P01 AG 17586-10, 1 U01 AG024904, AG 024904, UO1AG029213-01, P30AG036468, 2 P50 AG016570, 1 U01 AG 024904-05, P30 AG 10124-18, R01 AG031252, P01AG017586, U01AG010483, 1 U01 AG24904, 1P01 AG-19724-07, R01AG027859, P50AG023501, AG027859, P01 AG012435, AG-11378, 2P50AG005133, RC2AG036535, P01-AG19724, P01 AG 09215-20, R01-AG 10897, 2P30AG10129, R01 AG029672, R01 AG16381)
- National Heart, Lung, and Blood Institute (HL-095089, R01HL095089)
- National Institute of Mental Health (U01MH083506, MH 22005, MH062512, MH083506, R01MH079752, R01MH069433, MH083552, MH079752, R01 MH069259, 5 R01 MH071940, MH069433, R01MH072641, P30MH062512)
- National Institute on Drug Abuse (1 R01 DA017830)
- National Cancer Institute (2 P30 CA93373, CA104573)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK075128)
- National Institute of Neurological Disorders and Stroke (1 R01 NS050792, RL1NS062412, P50NS053488, 1 R01 NS049194, RC2NS069368, R01NS031966)
- National Institute of Biomedical Imaging and Bioengineering (1 U54 EB05149, 1 R01 EB 006266-01, U54EB005149, P01EB001955, 5R01EB002138-07)
- U.S. National Library of Medicine (2 R01LM005639)
- National Center for Research Resources (5 P41 RR013642, P41 RR-023953, U24RR021760, U54RR021813, R24 RR021382, R24 RR021992, KL2RR024144)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD050735, 1R01 HD053893-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, neuroimaging biomarkers, cerebrospinal fluid biomarkers, amyloid-beta 42, longitudinal cognitive change, normal aging, memory impairment, ADAS-Cog
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
